X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
arn-509 (34) 34
prostate cancer (25) 25
index medicus (23) 23
antitumor-activity (20) 20
antiandrogen (19) 19
enzalutamide (18) 18
humans (18) 18
male (18) 18
oncology (15) 15
abiraterone acetate (12) 12
pharmacology & pharmacy (12) 12
androgen receptor (11) 11
increased survival (11) 11
abiraterone (10) 10
cancer (10) 10
care and treatment (9) 9
castration (9) 9
prostatic neoplasms, castration-resistant - drug therapy (9) 9
urology & nephrology (9) 9
antineoplastic agents - therapeutic use (8) 8
apalutamide (8) 8
castration-resistant prostate cancer (8) 8
prostatic neoplasms - drug therapy (8) 8
androgens (7) 7
antiandrogens (7) 7
chemotherapy (7) 7
docetaxel (7) 7
galeterone (7) 7
metastasis (7) 7
safety (7) 7
thiohydantoins - therapeutic use (7) 7
androgen antagonists - therapeutic use (6) 6
apalutamide arn-509 (6) 6
double-blind (6) 6
inhibitor (6) 6
odm-201 (6) 6
orteronel (6) 6
phenylthiohydantoin - analogs & derivatives (6) 6
receptors, androgen - metabolism (6) 6
resistance (6) 6
review (6) 6
urology (6) 6
androgen receptor antagonists - therapeutic use (5) 5
bicalutamide (5) 5
flutamide (5) 5
mdv3100 (5) 5
medicine & public health (5) 5
phenylthiohydantoin - therapeutic use (5) 5
prostate (5) 5
prostatic neoplasms, castration-resistant - pathology (5) 5
survival (5) 5
androgen receptor antagonist (4) 4
androgen receptor antagonists (4) 4
androgen-receptor gene (4) 4
antineoplastic agents, hormonal - therapeutic use (4) 4
cancer therapies (4) 4
clinical trials as topic (4) 4
drug approval (4) 4
drug therapy (4) 4
expression (4) 4
health aspects (4) 4
ligands (4) 4
men (4) 4
neoplasm metastasis (4) 4
prostatic neoplasms - pathology (4) 4
research (4) 4
thiohydantoins - adverse effects (4) 4
thiohydantoins - pharmacology (4) 4
abridged index medicus (3) 3
aged (3) 3
androgen (3) 3
androgen antagonists - pharmacology (3) 3
androgen deprivation therapy (3) 3
androgen receptor antagonists - administration & dosage (3) 3
androgens - metabolism (3) 3
androstadienes - therapeutic use (3) 3
androstenes (3) 3
animals (3) 3
antiandrogen withdrawal (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic agents - adverse effects (3) 3
benzimidazoles - therapeutic use (3) 3
castration resistant prostate cancer (3) 3
cyp17 (3) 3
deoxyribonucleic acid--dna (3) 3
efficacy (3) 3
fda approval (3) 3
genetic aspects (3) 3
i clinical-trial (3) 3
ketoconazole (3) 3
metastasis-free survival (3) 3
mitoxantrone plus prednisone (3) 3
naphthalenes - therapeutic use (3) 3
open-label (3) 3
patients (3) 3
pharmacology/toxicology (3) 3
phase-ii (3) 3
progression (3) 3
prostate-specific antigen (3) 3
prostatic neoplasms (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 2019, Volume 42, pp. 4 - 6
Journal Article
Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 9, pp. 2264 - 2271
Background: Mutations in the androgen receptor (AR) ligand-binding domain (LBD), such as F877L and T878A, have been associated with resistance to... 
Apalutamide | Castration-resistant prostate cancer | Mutations | ARN-509 | Androgen receptor | androgen receptor | mutations | ANTIANDROGEN | ONCOLOGY | ABIRATERONE ACETATE | castration-resistant prostate cancer | ANTITUMOR-ACTIVITY | DOCETAXEL | apalutamide | ENZALUTAMIDE | Original
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2018, Volume 378, Issue 15, pp. 1408 - 1418
Journal Article
DRUGS, ISSN 0012-6667, 09/2019, Volume 79, Issue 14, pp. 1591 - 1598
Apalutamide (marketed as Erleada (R)) is an oral non-steroidal next-generation selective inhibitor of the androgen receptor (AR), and is approved in several... 
SPARTAN | APA | NMCRPC PATIENTS PTS | ANTIANDROGEN | EFFICACY | SAFETY | PHARMACOLOGY & PHARMACY | TOXICOLOGY | METASTASIS-FREE SURVIVAL | ARN-509 | ENZALUTAMIDE
Journal Article
Journal of Urology, ISSN 0022-5347, 11/2018, Volume 200, Issue 5, pp. 956 - 966
Purpose: Antiandrogens inhibit the androgen receptor and have an important role in the treatment of prostate cancer. This review provides a historical... 
neoplasm metastasis | androgen antagonists | androgen | receptors | castration | prostatic neoplasms | FOLLOW-UP | FLUTAMIDE | ANTITUMOR-ACTIVITY | BICALUTAMIDE | METASTATIC CARCINOMA | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | APALUTAMIDE ARN-509 | RAT PROSTATE | ENZALUTAMIDE | Antiandrogens | Care and treatment | Prostate cancer | Cancer
Journal Article
CANADIAN JOURNAL OF UROLOGY, ISSN 1195-9479, 06/2019, Volume 26, Issue 3, pp. 9782 - 9786
Urologists have been using oral nonsteroidal antiandrogens (AA) for 30 years as a component of combined androgen blockade. In February 2018, a new third... 
prostate cancer | castrate-resistant | antiandrogen | SAFETY | UROLOGY & NEPHROLOGY | ANTITUMOR-ACTIVITY | ARN-509 | apalutamide | non-metastatic disease
Journal Article
Saudi Pharmaceutical Journal, ISSN 1319-0164, 03/2019, Volume 27, Issue 3, pp. 368 - 372
Prostate cancer is the second deadliest cancer in the US and the fourth most common cancer among Saudi males. Patients usually present with non-metastatic... 
PHARMACOLOGY & PHARMACY | ANTIANDROGEN | ARN-509 | MEN | Drug therapy | Prostate cancer | Research
Journal Article
Expert Opinion on Investigational Drugs, ISSN 1354-3784, 06/2018, Volume 27, Issue 6, pp. 553 - 559
Introduction: Prostate cancer (PCa) is the most common cancer in elderly males. Androgen deprivation therapy (ADT) is still the cornerstone of initial... 
Apalutamide | prostate cancer | androgen receptor | anti-androgen | drug evaluation | ARN-509 | antagonist | ANTITUMOR-ACTIVITY | ANTIANDROGEN | RESISTANCE | PHARMACOLOGY & PHARMACY | THERAPIES | PHASE-I | ESTRO-SIOG GUIDELINES | ABIRATERONE | ENZALUTAMIDE
Journal Article
Chemistry – A European Journal, ISSN 0947-6539, 09/2019, Volume 25, Issue 51, pp. 11797 - 11819
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 05/2019, Volume 47, Issue 5, pp. 453 - 464
In this phase 1 study, the absolute bioavailability and absorption, metabolism, and excretion (AME) of apalutamide, a competitive inhibitor of the androgen... 
CHARACTERIZE | ANTIANDROGEN | ADME | ABSOLUTE BIOAVAILABILITY | CYSTEINE | PHARMACOLOGY & PHARMACY | INHIBITOR | ARN-509 | DISPOSITION | Urine | Expired air | Excretion | Intravenous administration | Profiling | Oral administration | Radioactive half-life | Mass spectroscopy | Carboxylic acids | Bioavailability | Metabolism | Infusion | Absorption | Metabolites | Hepatocytes | Feces | Intravenous infusion | Mass spectrometry | Carbon 14
Journal Article
Journal Article
Journal of Dalian Medical University, ISSN 1671-7295, 10/2015, Volume 37, Issue 5, pp. 502 - 506
Journal Article
FRONTIERS IN CHEMISTRY, ISSN 2296-2646, 07/2019, Volume 7, p. 474
Prostate Cancer (PCa) is the most frequently diagnosed cancer in men in their late '50s. PCa growth is mainly due to the activation of the androgen receptor by... 
prostate cancer | androgen receptor | molecular docking | ANDROGEN RECEPTOR ANTAGONISTS | ANTIANDROGEN | ADME | benzohydrazide | DYNAMICS | molecular dynamics | ARN-509 | HYDRAZIDE-HYDRAZONES | CHEMISTRY, MULTIDISCIPLINARY
Journal Article